Hematopoietic Stem Cell TransplantationTransplantation, AutologousStem Cell TransplantationTransplantation, HomologousSalvage TherapyPeripheral Blood Stem Cell TransplantationHodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsTransplantation ConditioningStem CellsMelphalanCombined Modality TherapyMultiple MyelomaTreatment OutcomeRemission InductionGraft vs Host DiseaseEtoposideDisease-Free SurvivalBone Marrow TransplantationCyclophosphamideRecurrenceHematologic NeoplasmsLymphoma, Non-HodgkinMyeloablative AgonistsCytarabineCarmustineSurvival RateSurvival AnalysisHematopoietic Stem Cell MobilizationHematopoietic Stem CellsRetrospective StudiesLiver TransplantationVincristineGraft SurvivalWhole-Body IrradiationDoxorubicinBusulfanPrognosisThiotepaMesenchymal Stem Cell TransplantationBone Marrow PurgingIfosfamideFollow-Up StudiesTransplantation ChimeraAntineoplastic AgentsTissue DonorsTime FactorsCord Blood Stem Cell TransplantationDexamethasoneLymphoma, Mantle-CellAmyloidosisAntigens, CD34Antibodies, Monoclonal, Murine-DerivedCell TransplantationAntineoplastic Agents, AlkylatingKidney TransplantationEmbryonic Stem CellsBoronic AcidsLymphomaPyrazinesGranulocyte Colony-Stimulating FactorCisplatinLymphoma, FollicularPrednisoneAdult Stem CellsLeukemia, Myeloid, AcuteChemotherapy, AdjuvantInduction ChemotherapyLeukapheresisHistocompatibility TestingNeoplasm Recurrence, LocalThalidomideAutograftsLymphoma, T-Cell, PeripheralLymphoma, Large B-Cell, DiffuseNeoplasm, ResidualImmunosuppressive AgentsMyelodysplastic SyndromesPodophyllotoxinHistocompatibilityProspective StudiesCell DifferentiationLeukemiaDrug Administration ScheduleGraft vs Leukemia EffectMaintenance ChemotherapyHeart TransplantationCarboplatinBleomycinPluripotent Stem CellsMesenchymal Stromal CellsVidarabineTransplantation ImmunologyNeoplasms, Second PrimaryLung TransplantationNeural Stem CellsStem Cell NicheLymphoma, B-CellMitoxantroneFatal Outcome